STREM2与MRI在阿尔茨海默病中的研究进展

云凌 刘(承德医学院附属医院，中国)
翠 赵(承德医学院附属医院，中国)

摘要

阿尔茨海默病（AD）是导致痴呆最常见的病因之一，目前AD的病理机制尚未完全阐明，且缺乏特异的治疗手段。寻找高敏感的早期生物标志物和检测方法对于疾病的诊断变得至关重要。可溶性髓样细胞触发性受体2（sTREM2）作为大脑小胶质细胞的激活物，被证实与AD的发生发展密切相关。磁共振成像（MRI）是一种非侵入性、多参数对比、高分辨率的诊断手段。在疾病的诊断中，多模态MRI可整合单一MRI模态的基础上提供关于组织形态、功能和代谢等多个方面的准确信息，能够更早地检测和管理疾病。因此，本综述聚焦于总结sTREM2作为生物标志物以及多模态MRI在AD的应用价值和研究进展，旨在提高疾病诊断和管理水平。

关键词

阿尔茨海默病；sTREM2；磁共振成像

参考

GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J].Lancet Neurol, 2019,18(1):88-106.

Zheng H, Jia L, Liu CC, et al. TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway[J]. J Neurosci, 2017 Feb 15,37(7):1772-1784.

Deczkowska A, Weiner A, Amit I. The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway[J]. Cell, 2020,181(6):1207-1217.

Ulland TK, Colonna M. TREM2- a key player in microglial biology and Alzheimer disease[J]. Nat Rev Neurol, 2018,14(11):667-675.

Guerreiro R, Wojtas A, Bras J, et al. Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer’s disease[J]. N Engl J Med, 2013 Jan 10;368(2):117-127.

Piccio L, Deming Y, Del-Águila JL, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status[J]. Acta Neuropathol, 2016,131(6):925-933.

Yang J, Fu Z, Zhang X, et al. TREM2 ectodomain and its soluble form in Alzheimer’s disease[J].Neuroinflammation, 2020,17(1):204.

Zhong L, Xu Y, Zhuo R, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model[J]. Nat Commun, 2019,10(1):1365.

Heslegrave A, Heywood W, Paterson R, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease[J]. Mol Neurodegener, 2016(11):3.

Liu D, Cao B, Zhao Y, et al. Soluble TREM2 changes during the clinical course of Alzheimer’s disease: A meta-analysis[J]. Neurosci Lett, 2018,686:10-16.

Bekris LM, Khrestian M, Dyne E, et al. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease[J]. Neuroimmunol, 2018,319:19-27.

Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology[J]. Mol Neurodegener, 2019,14(1):1.

Ferri E, Rossi PD, Geraci A, et al. The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?[J]. Front Mol Biosci, 2021(7):627931.

Gispert JD, Suárez-Calvet M, Monté GC, et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer’s disease[J]. Alzheimers Dement, 2016(12):1259-1272.

Rajagopalan P, Hibar DP, Thompson PM. TREM2 and neurodegenerative disease[J]. N Engl J Med, 2013,369(16):1565-1567.

Leng F, Zhan Z, Sun Y, et al. Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer’s Disease[J]. J Alzheimers Dis, 2022,88(1):117-126.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i3.16228